Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.
2.

Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines.

Coppola G, Besag F, Cusmai R, Dulac O, Kluger G, Moavero R, Nabbout R, Nikanorova M, Pisani F, Verrotti A, von Stülpnagel C, Curatolo P.

Eur J Paediatr Neurol. 2014 Nov;18(6):685-90. doi: 10.1016/j.ejpn.2014.05.008. Review.

PMID:
24929673
3.

Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview.

Wier HA, Cerna A, So TY.

Paediatr Drugs. 2011 Apr 1;13(2):97-106. doi: 10.2165/11586920-000000000-00000. Review.

PMID:
21351809
4.

Rufinamide: a pharmacoeconomic profile of its use as adjunctive therapy in Lennox-Gastaut syndrome.

McCormack PL.

Pharmacoeconomics. 2012 Mar;30(3):247-56. doi: 10.2165/11208630-000000000-00000. Review.

PMID:
22332960
5.

Rufinamide: a new antiepileptic medication for the treatment of seizures associated with lennox-gastaut syndrome.

Wisniewski CS.

Ann Pharmacother. 2010 Apr;44(4):658-67. doi: 10.1345/aph.1M679. Review.

PMID:
20233912
6.

lennox-Gastaut syndrome: an updateon treatment.

Carmant L, Whiting S.

Can J Neurol Sci. 2012 Nov;39(6):702-11. Review.

PMID:
23227575
7.

Rufinamide: a new anti-epileptic medication.

Hakimian S, Cheng-Hakimian A, Anderson GD, Miller JW.

Expert Opin Pharmacother. 2007 Aug;8(12):1931-40. Review.

PMID:
17696794
8.

Rufinamide: a new antiepileptic drug treatment for Lennox-Gastaut syndrome.

Ferrie CD.

Expert Rev Neurother. 2010 Jun;10(6):851-60. doi: 10.1586/ern.10.51. Review.

PMID:
20518600
9.

Rufinamide.

Deeks ED, Scott LJ.

CNS Drugs. 2006;20(9):751-60; discussion 761. Review.

PMID:
16953653
10.

Rufinamide for the treatment of Lennox-Gastaut syndrome.

Besag FM.

Expert Opin Pharmacother. 2011 Apr;12(5):801-6. doi: 10.1517/14656566.2011.560836. Review.

PMID:
21348771
11.

Rufinamide.

Arroyo S.

Neurotherapeutics. 2007 Jan;4(1):155-62. Review.

PMID:
17199032
12.

Management of seizures in Lennox-Gastaut syndrome.

Crumrine PK.

Paediatr Drugs. 2011 Apr 1;13(2):107-18. doi: 10.2165/11536940-000000000-00000. Review.

PMID:
21351810
13.

Treatment of Lennox-Gastaut syndrome.

Hancock EC, Cross HH.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD003277. doi: 10.1002/14651858.CD003277.pub2. Review. Update in: Cochrane Database Syst Rev. 2013;2:CD003277.

PMID:
19588340
14.

The efficacy and tolerability of pharmacologic treatment options for Lennox-Gastaut syndrome.

Montouris GD, Wheless JW, Glauser TA.

Epilepsia. 2014 Sep;55 Suppl 4:10-20. doi: 10.1111/epi.12732. Review. Erratum in: Epilepsia. 2015 Jun;56(6):984.

15.

Medical management of Lennox-Gastaut syndrome.

Michoulas A, Farrell K.

CNS Drugs. 2010 May;24(5):363-74. doi: 10.2165/11530220-000000000-00000. Review.

PMID:
20158289
16.

[Rufinamide. A review of its pharmacokinetic and pharmacodynamic properties].

Herranz JL.

Rev Neurol. 2008 Oct 1-15;47(7):369-73. Review. Spanish.

17.

Pharmacotherapy of epilepsy: newly approved and developmental agents.

Stephen LJ, Brodie MJ.

CNS Drugs. 2011 Feb;25(2):89-107. doi: 10.2165/11584860-000000000-00000. Review.

PMID:
21254787
18.

Rufinamide.

Heaney D, Walker MC.

Drugs Today (Barc). 2007 Jul;43(7):455-60. Review.

PMID:
17728846
19.

Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome.

Cramer JA, Sapin C, François C.

Acta Neurol Scand. 2013 Aug;128(2):91-9. doi: 10.1111/ane.12086. Review.

PMID:
23410109
20.

Lennox-Gastaut syndrome. Management update.

Al-Banji MH, Zahr DK, Jan MM.

Neurosciences (Riyadh). 2015 Jul;20(3):207-12. doi: 10.17712/nsj.2015.3.20140677. Review.

Items per page

Supplemental Content

Support Center